Not Tesla Or SpaceX But Anand Mahindra Thinks THIS Will Be Elon Musk's Most Enduring Gift To Humankind

Anand Mahindra said, "If this device lives up to these expectations, then, much more than Tesla or Space X, THIS will be your most enduring gift to humankind."

Anand Mahindra said that if THIS device lives up to these expectations, then, much more than Tesla or Space X, this will be Elon Musk's most enduring gift to humankind.

Source : PTI, X/@P_Kallioniemi

Elon Musk owned Neuralink received Breakthrough Device Designation from the FDA for Blindsight, following which the chairperson of Mahindra and Mahindra, Anand Mahindra, said that if this device lives up to its expectations, then it will be Musk's most enduring gift to humankind. This compliment from Mahindra came after Musk tweeted that the Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see.

Elon Musk tweeted, "The Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see. Provided the visual cortex is intact, it will even enable those who have been blind from birth to see for the first time. To set expectations correctly, the vision will be at first be low resolution, like Atari graphics, but eventually it has the potential be better than natural vision and enable you to see in infrared, ultraviolet or even radar wavelengths, like Geordi La Forge."

Anand Mahindra, while replying to this, said, "If this device lives up to these expectations, then, much more than Tesla or Space X, THIS will be your most enduring gift to humankind."

If this device lives up to these expectations then, much more than Tesla or Space X, THIS will be your most enduring gift to humankind. https://t.co/BtnbEEIvyn

— anand mahindra (@anandmahindra) September 19, 2024

The announcement of Blindsight follows a month after Elon Musk revealed that Neuralink plans to implant brain chips in eight additional patients in 2024.

Neuralink's Focus

Neuralink is currently recruiting participants for its PRIME study, a clinical trial aimed at testing its brain-computer interface (BCI) technology, which is designed to help people with quadriplegia control digital devices using their thoughts.

Earlier this year, Neuralink successfully implanted its device in a human patient for the first time. The patient has since used the BCI for tasks such as playing video games and engaging in online chess matches.

In 2022, Neuralink received FDA approval to transition from animal testing to human trials for its BCI technology.